AAAAAA

   
Results: 1-25 | 26-45
Results: 1-25/45
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia
Authors: Gore, SD Weng, LJ Zhai, S Figg, WD Donehower, RC Dover, GJ Grever, M Griffin, CA Grochow, LB Rowinsky, EK Zabalena, Y Hawkins, EK Burks, K Miller, CB
Citation: Sd. Gore et al., Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia, CLIN CANC R, 7(8), 2001, pp. 2330-2339
A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitorof thymidylate synthase, in patients with advanced solid malignancies
Authors: Schwartz, G Johnson, TR Goetz, A Burris, H Smetzer, L Lampkin, T Sailstad, J Hohneker, JA Von Hoff, DD Rowinsky, EK
Citation: G. Schwartz et al., A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitorof thymidylate synthase, in patients with advanced solid malignancies, CLIN CANC R, 7(7), 2001, pp. 1901-1911
A phase I and pharmacologic study of capecitabine and paclitaxel in breastcancer patients
Authors: Villalona-Calero, MA Blum, JL Jones, SE Diab, S Elledge, R Khoury, P Von Hoff, D Kraynak, M Moczygemba, J Kromelis, P Griffin, T Rowinsky, EK
Citation: Ma. Villalona-calero et al., A phase I and pharmacologic study of capecitabine and paclitaxel in breastcancer patients, ANN ONCOL, 12(5), 2001, pp. 605-614
Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel
Authors: Hidalgo, M Aylesworth, C Hammond, LA Britten, CD Weiss, G Stephenson, J Schwartz, G Patnaik, A Smith, L Molpus, K Felton, S Gupta, E Ferrante, KJ Tortora, A Sonnichsen, DS Skillings, J Rowinsky, EK
Citation: M. Hidalgo et al., Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel, J CL ONCOL, 19(9), 2001, pp. 2493-2503
Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies
Authors: Villalona-Calero, MA Eder, JP Toppmeyer, DL Allen, LF Fram, R Velagapudi, R Myers, M Amato, A Kagen-Hallet, K Razvillas, B Kufe, DW Von Hoff, DD Rowinsky, EK
Citation: Ma. Villalona-calero et al., Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies, J CL ONCOL, 19(3), 2001, pp. 857-869
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
Authors: Hidalgo, M Siu, LL Nemunaitis, J Rizzo, J Hammond, LA Takimoto, C Eckhardt, SG Tolcher, A Britten, CD Denis, L Ferrante, K Von Hoff, DD Silberman, S Rowinsky, EK
Citation: M. Hidalgo et al., Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies, J CL ONCOL, 19(13), 2001, pp. 3267-3279
Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties
Authors: Tolcher, AW Eckhardt, SG Kuhn, J Hammond, L Weiss, G Rizzo, J Aylesworth, C Hidalgo, M Patnaik, A Schwartz, G Felton, S Campbell, E Rowinsky, EK
Citation: Aw. Tolcher et al., Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties, J CL ONCOL, 19(11), 2001, pp. 2937-2947
Bioavailablility of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedine
Authors: O'Reilly, S Hartman, NR Bowling, KM Rowinsky, EK Donehower, RC Collins, J Strong, JM
Citation: S. O'Reilly et al., Bioavailablility of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedine, CANC CHEMOT, 48(3), 2001, pp. 223-228
Phase II study of 4-ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinoma
Authors: Lakhanpal, S Donehower, RC Rowinsky, EK
Citation: S. Lakhanpal et al., Phase II study of 4-ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinoma, INV NEW DR, 19(1), 2001, pp. 69-76
Pharmacokinetic profiles of doxorubicin in combination with taxanes
Authors: Holmes, FA Rowinsky, EK
Citation: Fa. Holmes et Ek. Rowinsky, Pharmacokinetic profiles of doxorubicin in combination with taxanes, SEMIN ONCOL, 28(4), 2001, pp. 8-14
Early clinical experience with farnesyl protein transferase inhibitors - From the bench to the bedside
Authors: Patnaik, A Rowinsky, EK
Citation: A. Patnaik et Ek. Rowinsky, Early clinical experience with farnesyl protein transferase inhibitors - From the bench to the bedside, CANC DRUG, 8, 2001, pp. 233-249
Oral paclitaxel and concurrent cyclosporin A: Targeting clinically relevant systemic exposure to paclitaxel
Authors: Britten, CD Baker, SD Denis, LJ Johnson, T Drengler, R Siu, LL Duchin, K Kuhn, J Rowinsky, EK
Citation: Cd. Britten et al., Oral paclitaxel and concurrent cyclosporin A: Targeting clinically relevant systemic exposure to paclitaxel, CLIN CANC R, 6(9), 2000, pp. 3459-3468
A Phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077
Authors: Britten, CD Rowinsky, EK Baker, SD Weiss, GR Smith, L Stephenson, J Rothenberg, M Smetzer, L Cramer, J Collins, W Von Hoff, DD Eckhardt, SG
Citation: Cd. Britten et al., A Phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077, CLIN CANC R, 6(1), 2000, pp. 42-49
Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model
Authors: Hammond, LA Hilsenbeck, SG Eckhardt, SG Marty, J Mangold, G MacDonald, JR Rowinsky, EK Von Hoff, DD Weitman, S
Citation: La. Hammond et al., Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model, EUR J CANC, 36(18), 2000, pp. 2430-2436
The rapamycin-sensitive signal transduction pathway as a target for cancertherapy
Authors: Hidalgo, M Rowinsky, EK
Citation: M. Hidalgo et Ek. Rowinsky, The rapamycin-sensitive signal transduction pathway as a target for cancertherapy, ONCOGENE, 19(56), 2000, pp. 6680-6686
A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenousinfusion in patients with advanced solid tumors
Authors: Tolcher, AW Aylesworth, C Rizzo, J Izbicka, E Campbell, E Kuhn, J Weiss, G Von Hoff, DD Rowinsky, EK
Citation: Aw. Tolcher et al., A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenousinfusion in patients with advanced solid tumors, ANN ONCOL, 11(3), 2000, pp. 333-338
Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies
Authors: Ochoa, L Hurwitz, HI Wilding, G Cohen, D Thomas, JP Schwartz, G Monroe, P Petros, WP Ertel, VP Hsieh, A Hoffman, C Drengler, R Magnum, S Rowinsky, EK
Citation: L. Ochoa et al., Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies, ANN ONCOL, 11(10), 2000, pp. 1313-1322
Plasma MMPs as surrogates of BAY 12-9566 - Reply
Authors: Eckhardt, SG Rowinsky, EK
Citation: Sg. Eckhardt et Ek. Rowinsky, Plasma MMPs as surrogates of BAY 12-9566 - Reply, J CL ONCOL, 18(8), 2000, pp. 1805-1806
Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil
Authors: Baker, SD Diasio, RB O'Reilly, S Lucas, VS Khor, SP Sartorius, SE Donehower, RC Grochow, LB Spector, T Hohneker, JA Rowinsky, EK
Citation: Sd. Baker et al., Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil, J CL ONCOL, 18(4), 2000, pp. 915-926
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies
Authors: Eckhardt, SG Baker, SD Britten, CD Hidalgo, M Siu, L Hammond, LA Villalona-Calero, MA Felton, S Drengler, R Kuhn, JG Clark, GM Smith, SL MacDonald, JR Smith, C Moczygemba, J Weitman, S Von Hoff, DD Rowinsky, EK
Citation: Sg. Eckhardt et al., Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies, J CL ONCOL, 18(24), 2000, pp. 4086-4097
Phase I and pharmacokinetic study of the differentiating agent vesnarinonein combination with gemcitabine in patients with advanced cancer
Authors: Patnaik, A Rowinsky, EK Tammara, BK Hidalgo, M Drengler, RL Garner, AM Siu, LL Hammond, LA Felton, SA Mallikaarjun, S Von Hoff, DD Eckhardt, SG
Citation: A. Patnaik et al., Phase I and pharmacokinetic study of the differentiating agent vesnarinonein combination with gemcitabine in patients with advanced cancer, J CL ONCOL, 18(23), 2000, pp. 3974-3985
DX-8951f, a hexacyclic camptothecin analog, on a daily times-five schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies
Authors: Rowinsky, EK Johnson, TR Geyer, CE Hammond, LA Eckhardt, SG Drengler, R Smetzer, L Coyle, J Rizzo, J Schwartz, G Tolcher, A Von Hoff, DD De Jager, RL
Citation: Ek. Rowinsky et al., DX-8951f, a hexacyclic camptothecin analog, on a daily times-five schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies, J CL ONCOL, 18(17), 2000, pp. 3151-3163
Population pharmacokinetic model for topotecan derived from phase I clinical trials
Authors: Gallo, JM Laub, PB Rowinsky, EK Grochow, LB Baker, SD
Citation: Jm. Gallo et al., Population pharmacokinetic model for topotecan derived from phase I clinical trials, J CL ONCOL, 18(12), 2000, pp. 2459-2467
Phase I and pharmacologic study of PN401 and fluorouracil in patients withadvanced solid malignancies
Authors: Hidalgo, M Villalona-Calero, MA Eckhardt, SG Drengler, RL Rodriguez, G Hammond, LA Diab, SG Weiss, G Garner, AM Campbell, E Davidson, K Louie, A O'Neil, JD von Borstel, R Von Hoff, DD Rowinsky, EK
Citation: M. Hidalgo et al., Phase I and pharmacologic study of PN401 and fluorouracil in patients withadvanced solid malignancies, J CL ONCOL, 18(1), 2000, pp. 167-177
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patientswith solid malignancies
Authors: Rowinsky, EK Humphrey, R Hammond, LA Aylesworth, C Smetzer, L Hidalgo, M Morrow, M Smith, L Garner, A Sorensen, JM Von Hoff, DD Eckhardt, SG
Citation: Ek. Rowinsky et al., Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patientswith solid malignancies, J CL ONCOL, 18(1), 2000, pp. 178-186
Risultati: 1-25 | 26-45